Arrowstreet Capital Limited Partnership Sells 63,188 Shares of Genmab A/S (NASDAQ:GMAB)

Arrowstreet Capital Limited Partnership cut its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 67.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,440 shares of the company's stock after selling 63,188 shares during the period. Arrowstreet Capital Limited Partnership's holdings in Genmab A/S were worth $635,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its position in Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company's stock valued at $636,000 after buying an additional 12,654 shares during the period. AIMZ Investment Advisors LLC bought a new stake in shares of Genmab A/S in the fourth quarter worth about $3,525,000. HighTower Advisors LLC purchased a new position in Genmab A/S during the 3rd quarter valued at about $273,000. Mirae Asset Global Investments Co. Ltd. raised its position in Genmab A/S by 229.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company's stock valued at $1,033,000 after purchasing an additional 34,652 shares during the last quarter. Finally, Blue Trust Inc. lifted its holdings in Genmab A/S by 33.4% in the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock worth $120,000 after buying an additional 1,442 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GMAB. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price for the company in a report on Thursday, February 13th. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Truist Financial lowered their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. Finally, BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $39.17.

Remove Ads

Genmab A/S Trading Up 0.2 %

GMAB stock traded up $0.04 during midday trading on Wednesday, reaching $19.55. 562,131 shares of the company's stock traded hands, compared to its average volume of 1,025,397. The stock has a market cap of $12.94 billion, a P/E ratio of 11.24, a PEG ratio of 2.65 and a beta of 1.07. The stock's 50-day moving average is $20.48 and its 200 day moving average is $21.24. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $30.41.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, research analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.